The epidural abscess treatment market size has grown strongly in recent years. It will grow from $41.11 billion in 2024 to $44.01 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increasing prevalence of epidural abscesses, high healthcare expenditure, increasing awareness of the disease, growing demand for combination therapies.
The epidural abscess treatment market size is expected to see strong growth in the next few years. It will grow to $56.78 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to growing geriatric population, government initiatives, investment in epidural abscess research and development, growing incidence of spinal epidural abscesses. Major trends in the forecast period include innovations in healthcare technology, digital health technologies in epidural abscess care, artificial intelligence (AI) in epidural abscess diagnosis and treatment, affordable epidural abscess treatments.
The growth of the epidural abscess treatment market is expected to be driven by the rising prevalence of neurological disorders. Neurological disorders encompass medical conditions that affect the nervous system, which includes the brain, spinal cord, and nerves. Common examples of neurological disorders include acute spinal cord injury, Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), among others. Epidural abscess treatment is a crucial approach for managing these neurological disorders. It typically involves timely surgical drainage of the abscess and antibiotic therapy, which helps prevent compression of the spinal cord and nerves, relieving pressure. For instance, as of March 2022, the Alzheimer's Association, a nonprofit organization in the United States, reported that approximately 6.7 million Americans aged 65 and older are living with Alzheimer's in 2023. This number is projected to increase to 12.7 million by 2050. Consequently, the growing prevalence of neurological disorders is serving as a driving factor for the expansion of the epidural abscess treatment market.
The growing prevalence of intravenous drug use is expected to drive the expansion of the epidural abscess treatment market in the future. Intravenous drug use involves injecting drugs directly into the bloodstream with a hypodermic needle and syringe. This practice can lead to epidural abscesses when contaminated needles or drugs introduce bacteria or pathogens into the bloodstream, increasing the occurrence of the condition and fueling demand for specialized treatments, care, and prevention programs. For example, in July 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, reported that in 2022-2023, 1.4% of individuals aged 14 and older had injected a drug at least once in their lifetime, while 0.2% had injected a drug within the past year. As a result, the rise in intravenous drug use is expected to drive the growth of the epidural abscess treatment market.
In March 2022, AbbVie Inc., a pharmaceutical company based in the United States, completed the acquisition of Syndesi Therapeutics SA for an approximate sum of $1 billion. This strategic acquisition is poised to facilitate AbbVie Inc.'s expansion within the field of neuroscience by incorporating novel synapse vesicle protein 2A modulators into its portfolio. Syndesi Therapeutics SA, headquartered in Belgium, is a biotechnology company with a focus on the development of therapies for spinal disorders, including conditions such as epidural abscesses.
Major companies operating in the epidural abscess treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma, Daiichi Sankyo Company Limited, Boehringer Ingelheim International GmbH, UCB Pharma, Sun Pharmaceutical Industries Limited, Kyowa Hakko Kirin Co. Ltd., Ferring B.V., Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Limited, Alembic Limited, Zydus Lifesciences Ltd., Lupin Limited, Mallinckrodt Pharmaceuticals.
North America was the largest region in the epidural abscess treatment market in 2024. The regions covered in epidural abscess treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the epidural abscess treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The epidural abscess treatment market consists of revenues earned by entities by providing surgical intervention, myelography, magnetic resonance imaging (MRI) and computed tomography (CT) scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The epidural abscess treatment market also includes sales of vancomycin, gentamicin and ceftriaxone. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
Epidural abscess treatment refers to the treatment of a rare disorder that is characterized by an infection in the area between the bones of the skull or spine and the membranes covering the brain and spinal cord. Epidural abscess treatment is used to manage symptoms, slow down the progression of the disease and prevent complications.
The main types of epidural abscesses are intracranial and intraspinal. An intracranial epidural abscess refers to an infection between the skull's bones and the membranes encasing the brain and spinal cord. These can be treated by various treatments, including antifungals, antibiotics and surgery, which are used by various end-users, such as hospitals, pharmacies, specialty clinics and others.
The epidural abscess treatment market research report is one of a series of new reports that provides epidural abscess treatment market statistics, including epidural abscess treatment industry global market size, regional shares, competitors with an epidural abscess treatment market share, detailed epidural abscess treatment market segments, market trends and opportunities and any further data you may need to thrive in the epidural abscess treatment industry. This epidural abscess treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Epidural Abscess Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on epidural abscess treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for epidural abscess treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The epidural abscess treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Intracranial; Intraspinal2) By Treatment: Antifungal; Antibiotics; Surgery
3) By End-User: Hospital; Pharmacy; Specialty Clinics; Other End-Users
Subsegments:
1) By Intracranial: Brain Abscess; Subdural Abscess; Epidural Abscess in the Cranium2) By Intraspinal: Cervical Epidural Abscess; Thoracic Epidural Abscess; Lumbar Epidural Abscess; Sacral Epidural Abscess
Key Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Epidural Abscess Treatment market report include:- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- AbbVie Inc.
- Bayer AG
- Novartis AG
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Abbott Laboratories
- Eli Lilly and Company
- Gilead Sciences Inc.
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Astellas Pharma
- Daiichi Sankyo Company Limited
- Boehringer Ingelheim International GmbH
- UCB Pharma
- Sun Pharmaceutical Industries Limited
- Kyowa Hakko Kirin Co. Ltd.
- Ferring B.V.
- Hikma Pharmaceuticals plc
- Intas Pharmaceuticals Limited
- Alembic Limited
- Zydus Lifesciences Ltd.
- Lupin Limited
- Mallinckrodt Pharmaceuticals
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | March 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 44.01 Billion |
Forecasted Market Value ( USD | $ 56.78 Billion |
Compound Annual Growth Rate | 6.6% |
Regions Covered | Global |
No. of Companies Mentioned | 29 |